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Editorial Comment 
Second Generation Calcium 
Channel Blockers In the 
Treatment of Chronic Heart 
Failure: Are They Any Better 
Than Their Predecessors?* 
MILTON PACKER, MD, FACC 
Not to be deficient in this particular, the author has provided 
himself with a moral . that the wrongdoing of one 
generation lives into the successive ones. 
Nathaniel Hawthorne 
The potential of using calcium channel blocking drugs in the 
treatment of chronic heart failure has generated a great deal 
of excitement since this approach was introduced into cardio- 
vascular medicine nearly 10 years ago. The calcium channel 
blockers are excellent systemic vasodilators and thus they 
can antagonize the deleterious vasoconstriction that contrib- 
utes to the syndrome of heart failure (1). These agents exert 
potent anti-ischemic effects. which can be therapeutically 
important in patients with heart failure whether or not they 
have large vessel coronary artery disease (2,3). The calcium 
channel blockers inhibit the influx of calcium into myocardial 
cells and thus interfere with a critical factor that may mediate 
the progression of cardiac dysfunction after an acute myocar- 
dial injury (4). For all of these reasons, cardiologists have long 
expected that these agents would prove as useful in the 
treatment of chronic heart failure as they have in the manage- 
ment of myocardial ischemia and systemic hypertension. 
Problems With the First Generation Calcium 
Channel Blockers 
Despite numerous attempts to demonstrate their utility, 
however, the promise of calcium channel blockers in the 
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treatment of chronic heart failure has not been fulfilled. 
Although all drugs in this category can produce short-term 
hemodynamic benefits, these initial effects are not necessar- 
ily sustained during long-term treatment (5,6). Even in 
patients who demonstrate long-term hemodynamic re- 
sponses, prolonged therapy is not accompanied by a lessen- 
ing of symptoms or an increase in exercise tolerance (6-9). 
The hemodynamic and clinical effects of the calcium channel 
blockers have generally proved less favorable than those of 
other vasodilator drugs (6,7). In addition, many patients with 
severe heart failure exhibit hemodynamic and symptomatic 
deterioration when treated with these agents; some develop 
severe hypotension and cardiogenic shock (10,ll). Finally, 
when calcium channel blockers are used in patients with left 
ventricular dysfunction recovering from an acute myocardial 
infarction, they appear to increase (rather than decrease) 
cardiovascular morbidity and mortality (12). Hence, despite 
a decade of anticipation and investigation, there is little 
evidence to support their use in the treatment of patients 
with heart failure. 
Why have the calcium channel blocking drugs failed to live 
up to their potential? Both the lack of efficacy as well as the 
risks of treatment have been traditionally attributed to the 
negative inotropic effects of these drugs. All calcium channel 
blocking drugs can depress cardiac contractility-an action 
that is greatly exaggerated in patients with chronic heart 
failure, who have a profound defect in the delivery of 
calcium to critical contractile proteins and thus are particu- 
larly susceptible to drugs than can further impair transmem- 
brane calcium transport (13). Furthermore, the normal abil- 
ity of the circulation to tolerate calcium channel blockade 
depends on its capacity to stimulate and respond to reflex 
activation of the sympathetic system, but these adrenergic 
reactions are markedly attenuated in chronic heart failure 
(14,15). The interaction of these mechanisms may explain 
why the short-term administration of verapamil, nifedipine 
and diltiazem has produced deleterious hemodynamic effects 
in patients with severe left ventricular dysfunction (16). 
Development of Second Generation Calcium 
Channel Blockers 
To circumvent these cardiodepressant risks, considerable 
efforts have been launched to develop “second generation” 
calcium channel blockers that can exert coronary and sys- 
temic vasodilator effects similar to those of nifedipine and 
diltiazem but are less likely to depress ventricular function. 
Such agents have been characterized as being “vasoselec- 
tive” because they show greater specificity for vascular 
tissue (as opposed to papillary muscle) than did the early 
calcium channel blockers (17). A variety of second genera- 
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tion calcium channel blocking agents (e.g., nicardipine, 
nisoldipine, nitrendipine, felodipine and isradipine) have 
been synthesized, their development in part motivated by 
the hope that they might be useful in the treatment of chronic 
heart failure. 
Clinical results in heart failure. When tested in the clini- 
cal setting, nicardipine, nisoldipine, nitrendipine, felodipine 
and isradipine have produced impressive short-term hemo- 
dynamic benefits in patients with chronic heart failure (18- 
22). Consistent with their vasoselective effects, these second 
generation calcium channel blockers appear to cause less 
cardiodepression in patients with impaired ventricular func- 
tion than do earlier agents in this class (23). In contrast to the 
experience with verapamil and nifedipine, heart failure has 
become worse in only a few patients during initiation of 
therapy with these new drugs. Unfortunately, this hemody- 
namic improvement-even if sustained after months of treat- 
ment-has not (to date) been accompanied by an increase in 
exercise capacity (7-9); instead, long-term therapy has fre- 
quently been accompanied by fluid retention and clinical 
deterioration (8,24). These unfavorable results with the 
second generation calcium channel blockers are strikingly 
similar to those reported with the first generation agents. 
Given their greater vascular selectivity, we should wonder 
why these new drugs have failed to improve the management 
of chronic heart failure. 
Factors Limiting the Response to Calcium 
Channel Blockers in Heart Failure 
The present study. Some investigators have suggested 
that, despite the apparent vascular selectivity of the second 
generation calcium channel blocking drugs, their negative 
inotropic potential remains their most important limitation. 
This possibility is supported by the study by Aroney and 
coworkers (25) that appears in this issue of the Journal. In 
12 of the 14 patients with chronic heart failure that were 
studied, nicardipine exerted a discernible cardiodepressant 
action, as indicated by a rightward shift in the left ven- 
tricular pressure-volume relation. This observation under- 
scores an important principle: no calcium channel blocker 
is free of negative inotropic effects. Even the new “vasose- 
lective” agents can impair cardiac contractility in the clinical 
setting. 
Importance of the negative inotropic effect. It seems un- 
likely that this cardiodepressant effect can explain the unfa- 
vorable responses seen in long-term studies with calcium 
channel blockers in chronic heart failure. Despite its nega- 
tive inotropic action, nicardipine still improved the cardiac 
performance of the patients studied by Aroney et al. (25) 
because the depression of cardiac contractility was offset by 
the vasodilator actions of the drug. In the absence of an 
adverse hemodynamic effect, there would appear to be no 
means by which the cardiodepressant effects of the calcium 
channel blockers could affect the clinical outcome of pa- 
tients. In fact, if the negative inotropic effects of these drugs 
(per se) were an important liability, we would anticipate that 
other agents that depress cardiac contractility (whether or 
not they were vasodilators) would also cause deleterious 
effects in chronic heart failure. However, both beta- 
adrenergic blockers and converting enzyme inhibitors can 
depress cardiac contractility in these patients (26,27), but 
their long-term use is associated with striking clinical bene- 
fits and a reduction in morbidity and mortality (28). More- 
over, if the long-term adverse effects of calcium channel 
blockers in left ventricular dysfunction were related to their 
cardiodepressant actions, we might expect the risks of 
treatment to be enhanced by beta-blockers, but this is not 
the case (12). These observations suggest that the negative 
inotropic action of the calcium channel blockers is not the 
most important factor that limits their clinical efficacy in 
chronic heart failure. 
Importance of neurohormonal activation. What mecha- 
nism can then explain the limited efficacy and risks of 
calcium channel blockers in these patients? Calcium channel 
blockers stimulate the release of vasoconstrictor neurohor- 
mones during short- and long-term treatment (1,5,24,29,30), 
whereas beta-blockers and converting enzyme inhibitors 
interfere with the action of endogenous neurohormonal 
systems. Is this difference clinically important? Neurohor- 
monal activation may unfavorably affect the clinical status of 
patients with heart failure by adversely affecting cardiac 
performance, by causing sodium retention and potassium 
depletion and by limiting the capacity of the peripheral 
vessels to dilate during exercise. Acting by these mecha- 
nisms, neurohormonal activation could account for the at- 
tenuated hemodynamic responses (5), limited changes in 
exercise capacity (6-9), fluid retention and hypokalemia (6,8) 
and progressive clinical deterioration (24) seen in controlled 
and uncontrolled studies with calcium channel blockers in 
heart failure. Neurohormonal activation has also been impli- 
cated in limiting the hemodynamic and clinical responses to 
other vasodilator drugs (31,32). This critical difference be- 
tween calcium channel blockers and converting enzyme 
inhibitors may be especially important in patients with 
marked neurohormonal activation before treatment, who 
seem to be the most likely to experience adverse hemody- 
namic effects with calcium channel blockers but favorable 
long-term clinical effects with converting enzyme inhibitors 
(33,34). 
Activation of the sympathetic nervous and renin- 
angiotensin systems may also explain the contrasting effects 
of calcium channel blockers and converting enzyme inhibi- 
tors on the survival of patients with left ventricular dysfunc- 
tion after an acute myocardial injury. Experimental studies 
(35,36) indicate that neurohormonal activation plays an 
important role in the progression of heart failure. In con- 
trolled clinical trials (28,37), agents that interfere with the 
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activity of these systems favorably modify the long-term 
outcome of these patients, whereas drugs that increase 
neurohormonal activity adversely affect prognosis. These 
observations suggest that the deleterious effects of cal- 
cium channel blockers on the survival of patients with 
left ventricular dysfunction after an acute myocardial in- 
farction may be related to the ability of these agents to 
stimulate neurohormonal systems rather than to their 
negative inotropic effects. Such a mechanism may explain 
how calcium channel blockers increase mortality in these 
patients without increasing the risk of worsening heart 
failure (12). 
Conclusions 
On the basis of the concepts just outlined, it seems likely 
that the major factor limiting the utility of calcium channel 
blockers (and perhaps most vasodilators) in the treatment of 
patients with chronic heart failure is the tendency of these 
drugs to stimulate endogenous neurohormonal systems. If 
this hypothesis is correct, we cannot expect that most of the 
second generation calcium channel blockers will prove use- 
ful in the management of these patients. These new drugs 
may have less cardiodepressant effect than the first genera- 
tion agents, but they are probably similar in their predilec- 
tion to activate neurohormonal systems during long-term 
therapy. 
Can calcium channel blockers be developed that do not 
enhance endogenous neurohormonal activity? The challenge 
will be difficult. Not only do calcium channel blockers 
stimulate the renin-angiotensin system by virtue of their 
hypotensive effects, but they may do so directly by inter- 
fering with the inhibitory effects of calcium on renin 
release (38). Furthermore, because they do not dilate 
venous capacitance vessels, the calcium channel blockers 
do not lower cardiac filling pressures during short- or 
long-term therapy. Yet, such a hemodynamic effect may 
be needed to reduce the heightened activity of the sym- 
pathetic nervous system in patients with heart failure 
(39), possibly because long-term decompression of the 
atria1 chambers partially restores baroreceptor function 
(14). Calcium channel blockers that directly enhance 
baroreflex responsiveness may be developed in the future. 
however (40). 
To meet these challenges, physicians and clinical inves- 
tigators must no longer focus only on the effects of various 
calcium channel blockers on cardiac contractility but must 
consider as well their actions on endogenous neurohormonal 
systems. Without this change in focus, drugs may be devel- 
oped that will have little therapeutic advantage over existing 
first and second generation agents and may be as likely to 
produce the same disappointing results in the treatment of 
patients with heart failure. 
The man who sees two or three generations is like the one 
who sits in the conjurer’s booth at a fair, and sees the tricks 
two or three times. They are meant to be seen only once. 
Arthur Schopenhauer 
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